Page 18«..10..17181920..»

Bone Therapeutics and Catalent sign agreements to streamline production of the allogeneic cell therapy product, ALLOB

By Dr. Matthew Watson

REGULATED INFORMATION

Read this article:
Bone Therapeutics and Catalent sign agreements to streamline production of the allogeneic cell therapy product, ALLOB

To Read More: Bone Therapeutics and Catalent sign agreements to streamline production of the allogeneic cell therapy product, ALLOB
categoriaGlobal News Feed commentoComments Off on Bone Therapeutics and Catalent sign agreements to streamline production of the allogeneic cell therapy product, ALLOB | dataOctober 29th, 2020
Read All

Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new…

By Dr. Matthew Watson

Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new treatment option in oncology

Original post:
Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new...

To Read More: Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new…
categoriaGlobal News Feed commentoComments Off on Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new… | dataOctober 29th, 2020
Read All

SparingVision Strengthens Management Team

By Dr. Matthew Watson

SparingVision Strengthens Management Team

More:
SparingVision Strengthens Management Team

To Read More: SparingVision Strengthens Management Team
categoriaGlobal News Feed commentoComments Off on SparingVision Strengthens Management Team | dataOctober 29th, 2020
Read All

Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER

By Dr. Matthew Watson

Q3 2020 sales growth(2) driven by strong Dupixent® and flu vaccines demand.

See the original post:
Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER

To Read More: Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER
categoriaGlobal News Feed commentoComments Off on Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER | dataOctober 29th, 2020
Read All

Polyphor completes recruitment in Phase III trial of balixafortide in metastatic breast cancer

By Dr. Matthew Watson

ALLSCHWIL, Switzerland, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN) today announces that it has completed recruitment in its FORTRESS Phase III study of balixafortide in metastatic breast cancer. A total of 411 patients have been recruited, including 323 in the third line cohort and 88 patients in the second line cohort. Although recruitment is closed, Polyphor will allow all patients that have already registered for the study to be enrolled. This may increase the final number of patients enrolled in the study to approximately 430. As previously communicated, data on the key primary endpoint of FORTRESS, progression free survival (PFS) in the overall population, is planned for Q4 2021. An analysis of the objective response rate (ORR) in eligible patients in third and later lines of chemotherapy is planned for Q2 2021.

Read more:
Polyphor completes recruitment in Phase III trial of balixafortide in metastatic breast cancer

To Read More: Polyphor completes recruitment in Phase III trial of balixafortide in metastatic breast cancer
categoriaGlobal News Feed commentoComments Off on Polyphor completes recruitment in Phase III trial of balixafortide in metastatic breast cancer | dataOctober 29th, 2020
Read All

Nicox Granted New Patent for NCX 470, Extending Exclusivity in Europe to 2039

By Dr. Matthew Watson

See the original post:
Nicox Granted New Patent for NCX 470, Extending Exclusivity in Europe to 2039

To Read More: Nicox Granted New Patent for NCX 470, Extending Exclusivity in Europe to 2039
categoriaGlobal News Feed commentoComments Off on Nicox Granted New Patent for NCX 470, Extending Exclusivity in Europe to 2039 | dataOctober 29th, 2020
Read All

AB Science announces a financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares

By Dr. Matthew Watson

NOT FOR DISTRIBUTION, PUBLICATION, RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN

Follow this link:
AB Science announces a financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares

To Read More: AB Science announces a financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares
categoriaGlobal News Feed commentoComments Off on AB Science announces a financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares | dataOctober 29th, 2020
Read All

Better Choice Closes Third Tranche of Series F and Completes Equity Raise Totaling Cumulative $21.7M

By Dr. Matthew Watson

Final Tranche is Anchored by Iconic Consumer Packaged Goods Private Equity Firm, Cambridge Companies SPG

Go here to read the rest:
Better Choice Closes Third Tranche of Series F and Completes Equity Raise Totaling Cumulative $21.7M

To Read More: Better Choice Closes Third Tranche of Series F and Completes Equity Raise Totaling Cumulative $21.7M
categoriaGlobal News Feed commentoComments Off on Better Choice Closes Third Tranche of Series F and Completes Equity Raise Totaling Cumulative $21.7M | dataOctober 27th, 2020
Read All

Rafael Pharmaceuticals Crosses Enrollment of 100th Patient in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory…

By Dr. Matthew Watson

Company continues meeting enrollment milestones across clinical trials amid the COVID-19 pandemic, putting patient safety first Company continues meeting enrollment milestones across clinical trials amid the COVID-19 pandemic, putting patient safety first

Read the rest here:
Rafael Pharmaceuticals Crosses Enrollment of 100th Patient in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory...

To Read More: Rafael Pharmaceuticals Crosses Enrollment of 100th Patient in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory…
categoriaGlobal News Feed commentoComments Off on Rafael Pharmaceuticals Crosses Enrollment of 100th Patient in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory… | dataOctober 27th, 2020
Read All

RespireRx Pharmaceuticals Inc. Announces Appointment of Dr. James Cook and Dr. Jeffrey Witkin as Research Fellows

By Dr. Matthew Watson

See the original post:
RespireRx Pharmaceuticals Inc. Announces Appointment of Dr. James Cook and Dr. Jeffrey Witkin as Research Fellows

To Read More: RespireRx Pharmaceuticals Inc. Announces Appointment of Dr. James Cook and Dr. Jeffrey Witkin as Research Fellows
categoriaGlobal News Feed commentoComments Off on RespireRx Pharmaceuticals Inc. Announces Appointment of Dr. James Cook and Dr. Jeffrey Witkin as Research Fellows | dataOctober 27th, 2020
Read All

BioStem Technologies, Inc. Announces Launch of AEON™

By Dr. Matthew Watson

Pompano Beach, Fl., Oct. 27, 2020 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company"), a leading life sciences company specializing in perinatal tissue allografts for use in regenerative therapies, today announced the launch of AEON™, the 6th and newest addition to the Company’s perinatal tissue allograft platform.

Go here to see the original:
BioStem Technologies, Inc. Announces Launch of AEON™

To Read More: BioStem Technologies, Inc. Announces Launch of AEON™
categoriaGlobal News Feed commentoComments Off on BioStem Technologies, Inc. Announces Launch of AEON™ | dataOctober 27th, 2020
Read All

Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress…

By Dr. Matthew Watson

NEW YORK and LONDON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announces that it will be presenting a poster during the 29th European Academy of Dermatology and Venereology (EADV) Congress being held virtually October 28 – November 1, 2020. The presentation will be posted onto Akari’s website.

Go here to read the rest:
Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress...

To Read More: Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress…
categoriaGlobal News Feed commentoComments Off on Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress… | dataOctober 27th, 2020
Read All

CohBar to Participate at ROTH Capital COVID-19 Therapeutics in Development Event

By Dr. Matthew Watson

MENLO PARK, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, and Chief Scientific Officer, Dr. Kenneth Cundy, will participate on the panel titled “Direct Antivirals and Other Agents Against SARS-CoV2 Virus” at the ROTH Capital COVID-19 Therapeutics in Development Event, being held virtually on October 28, 2020 at 7:30am PT. A live webcast of the presentation will be available for attendees who register at https://roth.zoom.us/webinar/register/WN_FF_LgnOeQmm7VsRye97DtQ.

Excerpt from:
CohBar to Participate at ROTH Capital COVID-19 Therapeutics in Development Event

To Read More: CohBar to Participate at ROTH Capital COVID-19 Therapeutics in Development Event
categoriaGlobal News Feed commentoComments Off on CohBar to Participate at ROTH Capital COVID-19 Therapeutics in Development Event | dataOctober 27th, 2020
Read All

Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update

By Dr. Matthew Watson

GAITHERSBURG, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19 vaccine candidate. NVX?CoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes Novavax’ proprietary Matrix?M™ adjuvant. The Company also announced that it will present data from its ongoing Phase 1/2 clinical trial, including new Phase 2 reactogenicity data, on Friday, October 30 during the United States (U.S.) Center for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices’ (ACIP) meeting.

Read this article:
Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update

To Read More: Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update
categoriaGlobal News Feed commentoComments Off on Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update | dataOctober 27th, 2020
Read All

Indus Holdings, Inc. to Report Third Quarter 2020 Financial and Operational Results

By Dr. Matthew Watson

California cannabis leader to host conference call on November 10, 2020 California cannabis leader to host conference call on November 10, 2020

Link:
Indus Holdings, Inc. to Report Third Quarter 2020 Financial and Operational Results

To Read More: Indus Holdings, Inc. to Report Third Quarter 2020 Financial and Operational Results
categoriaGlobal News Feed commentoComments Off on Indus Holdings, Inc. to Report Third Quarter 2020 Financial and Operational Results | dataOctober 27th, 2020
Read All

Galapagos’ R&D Roundtable showcases Toledo program

By Dr. Matthew Watson

Mechelen, Belgium; 27 October 2020, 16.15 CET – Galapagos NV (Euronext & NASDAQ: GLPG) unveils the Toledo target family as a series of salt-inducible kinase inhibitors. Toledo exhibits a dual mode of action characterized by enhanced transcription of anti-inflammatory cytokines and inhibited transcription of pro-inflammatory cytokines. Today, Galapagos also presents new preclinical and healthy volunteer data, and details its broad program to discover and develop multiple series of Toledo compounds with different selectivity profiles, aimed at treating a broad range of autoimmune conditions with important unmet medical need.

Follow this link:
Galapagos’ R&D Roundtable showcases Toledo program

To Read More: Galapagos’ R&D Roundtable showcases Toledo program
categoriaGlobal News Feed commentoComments Off on Galapagos’ R&D Roundtable showcases Toledo program | dataOctober 27th, 2020
Read All

Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs)

By Dr. Matthew Watson

NEW YORK and LONDON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it is confirming the timetable for the Accustem Sciences Limited ("Accustem") demerger (the "Demerger") for holders of the Company’s American Depositary Receipts (“ADRs”).

Read more:
Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs)

To Read More: Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs)
categoriaGlobal News Feed commentoComments Off on Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs) | dataOctober 27th, 2020
Read All

Sanofi: Information concerning the total number of voting rights and shares – September 2020

By Dr. Matthew Watson

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

More here:
Sanofi: Information concerning the total number of voting rights and shares - September 2020

To Read More: Sanofi: Information concerning the total number of voting rights and shares – September 2020
categoriaGlobal News Feed commentoComments Off on Sanofi: Information concerning the total number of voting rights and shares – September 2020 | dataOctober 27th, 2020
Read All

Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed…

By Dr. Matthew Watson

Initial results from pilot Phase 1/2 clinical trial in patients with locally advanced pancreatic cancer presented during virtual ASTRO Annual Meeting

Read the rest here:
Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed...

To Read More: Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed…
categoriaGlobal News Feed commentoComments Off on Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed… | dataOctober 27th, 2020
Read All

Lumos Pharma to Report Third Quarter 2020 Financial Results and Host a Conference Call on November 10, 2020

By Dr. Matthew Watson

AUSTIN, Texas, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its third quarter 2020 financial results after market close on Tuesday, November 10, 2020. The company will host a conference call and webcast at 4:30 PM ET that day to discuss its third quarter financial results and provide an update on corporate activities. There will also be a question and answer session following the prepared remarks.

Read more:
Lumos Pharma to Report Third Quarter 2020 Financial Results and Host a Conference Call on November 10, 2020

To Read More: Lumos Pharma to Report Third Quarter 2020 Financial Results and Host a Conference Call on November 10, 2020
categoriaGlobal News Feed commentoComments Off on Lumos Pharma to Report Third Quarter 2020 Financial Results and Host a Conference Call on November 10, 2020 | dataOctober 27th, 2020
Read All

Page 18«..10..17181920..»